Profile data is unavailable for this security.
About the company
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
- Revenue in USD (TTM)0.00
- Net income in USD-22.29m
- Incorporated2012
- Employees49.00
- LocationEnlivex Therapeutics Ltd14 Einstein St.NESS-ZIONA 7403618IsraelISR
- Phone+972 86623301
- Fax+972 86312981
- Websitehttps://www.enlivex.com/